MK-6598

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MK-6598, covering 2025-06-19 to 2026-07-15. Get the full timeline:

Most recent: Clinical Trial Results: A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) [Phase 1]

See pricing